These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
556 related items for PubMed ID: 27039410
41. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. Duintjer Tebbens RJ, Thompson KM. J Infect Dis; 2014 Nov 01; 210 Suppl 1():S485-97. PubMed ID: 25316871 [Abstract] [Full Text] [Related]
42. The bumpy road to polio eradication. Modlin JF. N Engl J Med; 2010 Jun 24; 362(25):2346-9. PubMed ID: 20573922 [No Abstract] [Full Text] [Related]
43. [Results of the Spanish National Campaign of oral vaccination polio 1963-1964: virological and epidemiological study]. Pérez Gallardo F, Valenciano Clavel L, Gabriel y Galán J. Rev Esp Salud Publica; 2013 Jun 24; 87(5):523-40. PubMed ID: 24322289 [Abstract] [Full Text] [Related]
44. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. Ion-Nedelcu N, Strebel PM, Toma F, Biberi-Moroeanu S, Combiescu M, Persu A, Aubert-Combiescu A, Plotkin SA, Sutter RW. J Infect Dis; 1997 Feb 24; 175 Suppl 1():S241-6. PubMed ID: 9203723 [Abstract] [Full Text] [Related]
45. Inactivated poliovirus vaccine and vaccine-associated paralytic poliomyelitis. Brown B. JAMA; 1997 Feb 24; 277(4):295. PubMed ID: 9002483 [No Abstract] [Full Text] [Related]
47. [Effectiveness of different strategies of vaccine prophylaxis for poliomyelitis in the Ukraine]. Moĭseieva HV, Zadorozhna VI. Lik Sprava; 2002 Apr 24; (2):85-8. PubMed ID: 12073271 [Abstract] [Full Text] [Related]
48. Anti-polio vaccinations in the third millennia. Icardi G, Tassinari F. Ann Ig; 2018 Apr 24; 30(4 Supple 1):11-15. PubMed ID: 30062374 [Abstract] [Full Text] [Related]
49. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA, Chilean IPV/bOPV study group. Lancet Infect Dis; 2015 Nov 24; 15(11):1273-82. PubMed ID: 26318714 [Abstract] [Full Text] [Related]
53. Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas. Pedreira C, Thrush E, Jauregui B. J Infect Dis; 2017 Jul 01; 216(suppl_1):S76-S85. PubMed ID: 28838161 [Abstract] [Full Text] [Related]
54. Polio eradication, cessation of vaccination and re-emergence of disease. Minor PD. Nat Rev Microbiol; 2004 Jun 01; 2(6):473-82. PubMed ID: 15152203 [No Abstract] [Full Text] [Related]
57. Change from oral poliovirus vaccine to inactivated poliovirus vaccine. Mele A, Jefferson T, Franco E, Salmaso S. Lancet; 2002 Oct 12; 360(9340):1178. PubMed ID: 12387987 [No Abstract] [Full Text] [Related]
59. The future of polio immunization in the United States: are we ready for change? Paradiso PR. Pediatr Infect Dis J; 1996 Aug 12; 15(8):645-9. PubMed ID: 8858665 [No Abstract] [Full Text] [Related]